Potential application as screening and drug designing tools of cytoarchitectural deficiencies present in three animal models of schizophrenia
- 8 March 2009
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Drug Discovery
- Vol. 4 (3), 257-278
- https://doi.org/10.1517/17460440902762794
Abstract
Background: The development of new treatment alternatives for schizophrenia has been prevented by the unknown etiology of the illness and the divergence of results in the field. However, consistent neuropathological findings are emerging from anatomical areas known to be at the core of schizophrenia. If these deficiencies are replicated in animal models then such anomalies could become the target for a new generation of drugs. Objective: To determine if the methylazoxymethanol acetate (MAM) model, the heterozygote reeler mouse (HRM) and NMDA-antagonists treated rats replicate neuropathological deficits encountered in patients with schizophrenia and to establish if such changes could lead the search for developing novel treatment alternatives. Methods: Databases including MEDLINE, Cochrane and Ovid were searched; search terms included neuropathology, schizophrenia and animal models. Results/conclusions: NMDA-antagonist treated animals partially replicate schizophrenia anomalies in parvalbumin positive interneurons. In contrast, neuroanatomical deficiencies replicated by the MAM model and the HRM in the hippocampus and the prefrontal cortex seem promising targets for future pharmacological research in schizophrenia. Such neuroanatomical findings along with evidence from molecules and genes associated with schizophrenia suggest new drugs should aim to correct deficits in the formation of dendrites and axons that seems to be implicated in this illness pathophysiology.Keywords
This publication has 133 references indexed in Scilit:
- Reinforcement and Reversal Learning in First-Episode PsychosisSchizophrenia Bulletin, 2008
- Morphogenesis and regulation of Bergmann glial processes during Purkinje cell dendritic spine ensheathment and synaptogenesisGlia, 2008
- Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trialNature Medicine, 2007
- Probabilistic reversal learning impairments in schizophrenia: Further evidence of orbitofrontal dysfunctionSchizophrenia Research, 2007
- Astrocytic control of synaptic NMDA receptorsJournal Of Physiology-London, 2007
- Neuroanatomical phenotypes in the Reeler mouseNeuroImage, 2007
- Assessment of cognitive function in the heterozygous reeler mousePsychopharmacology, 2006
- A Neurobehavioral Systems Analysis of Adult Rats Exposed to Methylazoxymethanol Acetate on E17: Implications for the Neuropathology of SchizophreniaBiological Psychiatry, 2006
- A schizophrenia-associated mutation of DISC1 perturbs cerebral cortex developmentNature, 2005
- Circumscribed malformation and nerve cell alterations in the entorhinal cortex of schizophrenicsJournal of Neural Transmission, 1994